← Leaderboards
Jennifer Lynn Goldman
Children'S Mercy Hosp (Kansas City, Mo)
$4,709,020
Attributed
$9,060,449
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,060,449 · 6
By mechanism
OT2$4,999,682 · 1
TL1$1,608,195 · 1
R01$1,364,567 · 1
R35$433,669 · 1
T32$428,421 · 1
P20$225,915 · 1
Top collaborators
- Jacob J. Sosnoff3 shared
- Dana Keener Mast2 shared
- Jennifer E Schuster2 shared
- Jonathan Wagner2 shared
- Nicole L Nollen1 shared
Most similar at Children'S Mercy Hosp (Kansas City, Mo)
Same institution · by research overlap
- James Steven Leeder$15,267,008
Others in their field
Other Emerging Leaders on “Future”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- John E West · University Of Texas At Austin$128,483,161
- Beth Baseler · Leidos Biomedical Research, Inc.$117,364,154
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
Research focus
FutureClinical ResearchInnovationTranslational ResearchCohortChildTrimethoprim-SulfamethoxazoleAdductReactionInsightAntibioticsProteinsLiver InjuryBiological MarkersGeneticBaseHla AntigensAllelesImmunologicsEventPharmaceutical PreparationsAdverse ReactionsAntigensCombined Antibiotics
Grant awards (15)
An integrative approach to identify biomarkers and investigate mechanisms of adverse drug reactions$433,669
R35 · FY2025 · GM · contact PI
NRSA Training Core$426,072
TL1 · FY2025 · TR
NRSA Training Core$306,601
TL1 · FY2024 · TR
NRSA Training Core$443,745
TL1 · FY2023 · TR
Support for Safe Return to in-Person School: COVID-19 Testing, Learning, and Consultation (School TLC)$1,999,702
OT2 · FY2022 · HD
NRSA Training Core$431,777
TL1 · FY2022 · TR
Trimethoprim: an overlooked contributor of trimethoprim-sulfamethoxazole idiosyncratic adverse drug reactions$267,702
R01 · FY2022 · GM · contact PI
Children's Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology$173,149
T32 · FY2022 · HD
Support for Safe Return to in-Person School: COVID-19 Testing, Learning, and Consultation (School TLC)$2,999,980
OT2 · FY2021 · HD
Trimethoprim: an overlooked contributor of trimethoprim-sulfamethoxazole idiosyncratic adverse drug reactions$267,702
R01 · FY2021 · GM · contact PI
Children's Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology$255,272
T32 · FY2021 · HD
Trimethoprim: an overlooked contributor of trimethoprim-sulfamethoxazole idiosyncratic adverse drug reactions$267,702
R01 · FY2020 · GM · contact PI
Trimethoprim: an overlooked contributor of trimethoprim-sulfamethoxazole idiosyncratic adverse drug reactions$268,235
R01 · FY2019 · GM · contact PI
Determining the Mechanisms of Trimethoprim-Sulfamethoxazole Idiosyncratic Adverse Drug Reactions$225,915
P20 · FY2019 · GM · contact PI
Trimethoprim: an overlooked contributor of trimethoprim-sulfamethoxazole idiosyncratic adverse drug reactions$293,226
R01 · FY2018 · GM · contact PI